Clinical Trial

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 27, 2022 (before its estimated October 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial is a single-center, single-arm, prospective clinical study to investigate the efficacy and safety of zanubrutinib maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL) in Initial remission. The patients were divided into two categories: 1) Zanubrutinib maintenance therapy was started after R-CHOP induction and consolidation therapy reached maximum efficacy; 2) Initiate zanubrutinib maintenance therapy after maximal response to induction and consolidation therapy with or without rituximab (R-chemo). Therefore, the data in this study will reflect the efficacy and safety of zanubrutinib in the maintenance treatment of DLBCL patients with initial remission, and will provide new insights into the clinical application of zanubrutinib.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05596097
Lead Sponsor LanZhou University
Collaborators: BeOne Medicines
Conditions Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment 15 participants
Start Date 2022-10-30
Primary Completion 2024-10-20 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2022-10-27